Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia

References

• Buckley SA, Othus M, Estey EH, et al. The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. Blood Cancer J. 2015;5:e276
   PubMed Web of Science ®Google Scholar
• Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(1):175–187.
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332(25):1678–1683.
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332(25):1671–1677.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90(12):4710–4718.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, for The International Acute Myeloid Leukemia Study Group, et al. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia. 2006;20(3):404–409.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Hynes D, Godwin J, Southwest Oncology Group, et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest. 2001;19(6):603–610.
   PubMed Web of Science ®Google Scholar
• Asano Y, Okamura S, Shibuya T, et al. Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. Blood. 1988;72(5):1682–1686.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591–2597.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines: Acute Myeloid Leukemia (version 3). 2019. [cited 2019 May 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
   Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Lexi-Drugs [internet]. Hudson, OH: Lexicomp; [cited 2020 Feb 1]. Available from: http://online.lexi.com/.
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP) [internet]. Rockville, MD: Agency for Healthcare Research and Quality; [updated Dec 2019]. [cited Feb 2020]. Available from: www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp.
   Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27–34.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, Eastern Cooperative Oncology, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479–485.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453–461.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90(8):2952–2961.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, Swiss Group for Clinical Cancer Research, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743–752.
   PubMed Web of Science ®Google Scholar
• Löfgren C, Paul C, Aström M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol. 2004;124(4):474–480.
   PubMed Web of Science ®Google Scholar
• Maslak PG, Weiss MA, Berman E, et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia. 1996;10(1):32–39.
   PubMed Web of Science ®Google Scholar
• Bradstock K, Matthews J, Young G, The Australian Leukaemia Study Group, et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia. 2001;15(9):1331–1338.
   PubMed Web of Science ®Google Scholar
• Usuki K, Urabe A, Masaoka T, Gran AML Study Group, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol. 2002;116(1):103–112.
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91(10):3607–3615.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86(2):457–462.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, American Society of Clinical Oncology, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, European LeukemiaNet, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 1999;10(2):177–182.
   PubMed Web of Science ®Google Scholar